

f in @TakedaOncology

Learn more at TakedaOncology.com

©2023 Takeda Pharmaceuticals U.S.A., Inc.



ABSTRACT # TITLE SESSION **LEUKEMIAS** PhALLCON: A Phase 3 Study Comparing Ponatinib Versus **ORAL PRESENTATION** ABSTRACT Imatinib in Newly Diagnosed Ph+ALL **S110** Friday, June 9, 2023 2:45-4:00 PM CEST Location: Panorama 3 POSTER PRESENTATION Post Hoc Analysis of Patient Responses by T315I **ABSTRACT** Mutation Status From the 3-Year Update of the OPTIC Friday, June 9, 2023 P662 Trial: A Dose-Optimization Study of 3 Starting Doses 6:00-7:00 PM CEST of Ponatinib Location: Poster Area Early Cytogenetic or Molecular Landmark Response **POSTER PRESENTATION ABSTRACT** to Ponatinib Treatment Predicts Outcomes in Heavily Friday, June 9, 2023 P670 Pretreated Patients with Chronic-phase Chronic Myeloid 6:00-7:00 PM CEST Leukemia in PACE: 5-year data Location: Poster Area

MULTIPLE MYELOMA

ABSTRACT P929 Circulating Tumor DNA Assessment Improves Prognostic Prediction in Relapsed/Refractory Multiple Myeloma Receiving Ixazomib, Lenalidomide, and Dexamethasone

POSTER PRESENTATION

Friday, June 9, 2023 6:00-7:00 PM CEST Location: Poster Area



For more information, please see **EHA online program**.



